Abstracts / Abstrakts
1 2 3 4 5 6 7 8
- 95) Belz GG, Butzer R, Kober S, Mang C, Mutschler E, Greater extent and duration of antagonism of irbesartan on angiotensin ll pressor response and radioligand binding in man compared to losartan and valsartan. S Afr J Sci 1998;94:V.
- 96) Belz GG, Mang C, Butzer R, Breithaupt-Grögler K, Fuchs W. Candesartan cilexetil has the highest pharmacologic potency of various AT1 antagonists – assessed by the Schild regression technique in man. J Hypertension 1999;17(Suppl.3):S66.
- 97) Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Greater extent and duration of antagonism of Irbesartan on angiotensin ll pressor response and radioligand binding in man compared to Losartan and Valsartan. J Am Coll Cardiol 1999;33(Suppl.A): 284A-285A.
- 98) Kober S, Butzer R, Mang C, Rönz T, Hausdorf C, Langguth P, Belz GG. Mutschler E. Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan cilexetil. N S Arch Pharmacol 2000;361(Suppl.):R 130.
- 99) Kober S, Butzer R, Langguth P, Mang C, Hausdorf C, Roenz T, Belz GG. Mutschler E. Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan cilexetil. Am J Hypertens 2000;13:150A.
- 100) Belz GG, Butzer R, Kober S, Langguth P, Mang C, Hausdorf C, Roenz T, Mutschler E. Irbesartan results in more complete blockade of human renal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by higher plasma renin levels. Am J Hypertens 2000;13:151A.
- 101) Belz GG, Mang C, Butzer R, Breithaupt-Grögler K. Comparative potency of various AT1 antagonists using the Schild regression technique in man. J Hypertens 2000;18(Suppl.2): S158.
- 102) Kober S, Butzer R, Langguth P, Mang C, Hausdorf C, Roenz T, Belz GG, Mutschler E. Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan cilexetil. J Hypertens 2000;18(Suppl.2):S209.
- 103) Butzer R, Belz GG, Kober S, Langguth P, Mang C, Hausdorf C, Roenz T, Mutschler E. Irbesartan results in more complete blockade of human adrenal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by blunted plasma aldosterone levels. J Hypertens 2000;18(Suppl.2):S209.
- 104) Belz GG, Butzer R, Kober S, Langguth P, Mang C, Hausdorf C, Roenz T, Mutschler E. Irbesartan results in more complete blockade of human renal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by higher plasma renin levels. Eur J Clin Pharmacol 2000;56:A19.
- 105) Barry M, Belz G, Roll S, O'Grady P, Swaminathan A, Geraldes M, Mangold B. Interaction of nelfinavir with atorvastatin and pravastatin in normal healthy volunteers. AIDS 2000;14(Suppl.4):S90.
- 106) Belz GG, Butzer R. A clinical pharmacological approach for characterizing AT1 receptor antagonists. Eur J Clin Pharmacol 2001;57:A20.
- 107) Belz GG, Breithaupt-Grögler K, Roll S, Mangold B, Reeves RA, Strack E. Differential effects of omapatrilat and hydrochlorothiazide on arterial function in hypertension. Eur Heart J 2002;23(Suppl):327.